Anti-DRAXI/ DRAXIN/ AGPA3119 functional antibody

Anti-DRAXI/ DRAXIN/ AGPA3119 functional antibody for cell culture, ELISA & in-vivo assay

Target products collectionGo to DRAXIN/DRAXIN products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)


Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-SE0162-Ab-1/ GM-Tg-hg-SE0162-Ab-2Anti-Human DRAXIN monoclonal antibodyHuman
GM-Tg-rg-SE0162-Ab-1/ GM-Tg-rg-SE0162-Ab-2Anti-Rat DRAXIN monoclonal antibodyRat
GM-Tg-mg-SE0162-Ab-1/ GM-Tg-mg-SE0162-Ab-2Anti-Mouse DRAXIN monoclonal antibodyMouse
GM-Tg-cynog-SE0162-Ab-1/ GM-Tg-cynog-SE0162-Ab-2Anti-Cynomolgus/ Rhesus macaque DRAXIN monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-SE0162-Ab-1/ GM-Tg-felg-SE0162-Ab-2Anti-Feline DRAXIN monoclonal antibodyFeline
GM-Tg-cang-SE0162-Ab-1/ GM-Tg-cang-SE0162-Ab-2Anti-Canine DRAXIN monoclonal antibodyCanine
GM-Tg-bovg-SE0162-Ab-1/ GM-Tg-bovg-SE0162-Ab-2Anti-Bovine DRAXIN monoclonal antibodyBovine
GM-Tg-equg-SE0162-Ab-1/ GM-Tg-equg-SE0162-Ab-2Anti-Equine DRAXIN monoclonal antibodyEquine

Size: 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-SE0162-Ab-1/ GM-Tg-hg-SE0162-Ab-2; GM-Tg-rg-SE0162-Ab-1/ GM-Tg-rg-SE0162-Ab-2;
GM-Tg-mg-SE0162-Ab-1/ GM-Tg-mg-SE0162-Ab-2; GM-Tg-cynog-SE0162-Ab-1/ GM-Tg-cynog-SE0162-Ab-2;
GM-Tg-felg-SE0162-Ab-1/ GM-Tg-felg-SE0162-Ab-2; GM-Tg-cang-SE0162-Ab-1/ GM-Tg-cang-SE0162-Ab-2;
GM-Tg-bovg-SE0162-Ab-1/ GM-Tg-bovg-SE0162-Ab-2; GM-Tg-equg-SE0162-Ab-1/ GM-Tg-equg-SE0162-Ab-2
Products NameAnti-DRAXIN monoclonal antibody
Formatmab
Target NameDRAXIN
Protein Sub-locationSecreted Protein/Potential Cytokines
Category of antibodyFACS/Biofunctional Antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)
IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by ELISA with recombinant soluble protein antigen. The biofunction of antibodies are validated with in-vitro assay (IC50 or EC50 TBD).
TagFc
Products descriptionPre-made anti-DRAXIN benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenGM-Tg-g-SE0162-Ag-1Recombinant multi-species DRAXI/ DRAXIN/ AGPA3119 protein


    Target information

    Target IDGM-SE0162
    Target NameDRAXIN
    Gene ID374946,70433,691317,714633,487442,101099890,506110,100056289
    Gene Symbol and Synonyms2610109H07Rik,AGPA3119,C16H1orf187,C1H1orf187,C1orf187,C2H1orf187,DRAXIN,neucrin,UNQ3119
    Uniprot AccessionQ8NBI3,P0C8S2
    Uniprot Entry NameDRAXI_HUMAN,DRAXI_BOVIN
    Protein Sub-locationSecreted Protein/Potential Cytokines
    Category
    DiseaseN/A
    Gene EnsemblENSG00000162490
    Target ClassificationN/A

    The target: DRAXIN, gene name: DRAXIN, also named as AGPA3119, C1orf187, UNQ3119, neucrin. Predicted to be involved in negative regulation of canonical Wnt signaling pathway; negative regulation of neuron projection development; and nervous system development. Predicted to act upstream of or within negative regulation of axon extension and negative regulation of neuron apoptotic process. Predicted to be active in extracellular region. [provided by Alliance of Genome Resources, Apr 2022].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.